Peter Zafirides, MD
Psychiatry · Columbus, OHNPI 1699845388
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $94,465 of the $108,886 with a category attached, or 86.8%. AbbVie accounts for 84.2% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $34,204 and has fallen 69.7% since, to $10,351 in 2025. Among psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $270.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$92K
- Johnson & Johnson$16K
- Lundbeck LLC$281
- Otsuka America Pharmaceutical, Inc.$227
- Takeda Pharmaceuticals U.S.A., Inc.$203
- Avanir Pharmaceuticals, Inc.$91
- plus $174 from 7 others
What the payments were for
- Consulting fees$6,0606%
- Speaking & faculty fees$94,46587%
- Travel & lodging$4,4624%
- Food & beverage$3,8984%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 286 | $91,704 |
| Johnson & Johnson | 43 | $16,206 |
| Lundbeck LLC | 23 | $281 |
| Otsuka America Pharmaceutical, Inc. | 16 | $227 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $203 |
| Avanir Pharmaceuticals, Inc. | 6 | $91 |
| Vanda Pharmaceuticals Inc. | 2 | $63 |
| Shire North American Group Inc | 2 | $31 |
| Ironshore Pharmaceuticals Inc. | 2 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Neuronetics, Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,886 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 59 | $82,364 |
| TrintellixVortioxetine Hydrobromide | 47 | $39,844 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 80 | $5,820 |
| Lurasidone Hcl | 24 | $4,663 |
| Bupropion XlBupropion Hcl | 253 | $4,638 |
| Aripiprazole | 65 | $3,558 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 99 | $3,389 |
| Buspirone Hcl | 136 | $3,004 |
| Lisdexamfetamine Dimesylate | 12 | $2,811 |
| Duloxetine Hcl | 120 | $2,719 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 68 | $2,677 |
| Vilazodone Hcl | 45 | $2,199 |
| Clonazepam | 210 | $2,095 |
| Quetiapine Fumarate | 79 | $1,644 |
| Olanzapine | 62 | $1,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $91,704 | $82,36459 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $203 | $39,84447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Columbus
- Fred RomeoColumbus$2.3M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Dallas ErdmannColumbus$125K
- Daniel LeeColumbus$63K
- Pavan DontineniColumbus$32K
- Henry NasrallahCincinnati$3.8M
- Amita PatelDayton$2.1M
- Pradeep ManudhaneCanton$1.5M
- Binit ShahCleveland$913K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.